Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases That Affect the Skin

Summary

Strategic Combination Brings Highly Innovative Late Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB)